Oncotherics Poland Sp. zo.o. is delighted to announce that it has secured a 11.7M PLN grant as part of the regional operational program of the Małopolskie Voivodeship for the years 2014-2020.

The 19.4M PLN drug development programme will progress the company’s patented asset – OCT1002 – from drug manufacturing and formulation, through a preclinical toxicology programme and on to a Phase I clinical trial in Poland.

wartość projektu: 19 357 662,37 PLN
wkład funduszy Europejskich: 11 718 069,36 PLN